Skip to main content
Phase 2 Study of Brentuximab Vedotin plus Ibrutinib for Patients with Relapsed/Refractory Hodgkin Lymphoma
Read More
Preliminary Results of Prophylactic Tocilizumab After Axicabtagene Ciloleucel (axi-cel; KTE-C19) Treatment for Patients with Relapsed/Refractory, Aggressive NHL
Read More
Median 3.5-Year Follow-Up of Ibrutinib Treatment in Patients with Relapsed/Refractory Mantle-Cell Lymphoma: A Pooled Analysis
Read More
Adverse Events, Resource Use, and Economic Burden in Patients with Mantle-Cell Lymphoma in the United States
Read More
Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (GA101) for First-Line Treatment of Patients with CLL with Mutated IGHV and without TP53 Aberrations
Read More
Meeting Highlights
ASH Highlights
Nivolumab plus Azacitidine Shows Encouraging Activity in R/R AML or as Frontline Therapy in Elderly Patients with AML
Read More
Meeting Highlights
ASH Highlights
Safety and Tolerability of Midostaurin from Expanded Treatment Protocol in Patients with FLT3 Mutation–Positive, Newly Diagnosed AML
Read More
Meeting Highlights
ASH Highlights
Encouraging Efficacy and Safety with Enasidenib or Ivosidenib plus Azacitidine in Patients with Newly Diagnosed AML
Read More
Meeting Highlights
ASH Highlights
Enasidenib Monotherapy Is Well-Tolerated and Active in Older Patients with Untreated mIDH2 AML
Read More
Breast Cancer
Immunotherapy Continues to Gain Momentum in Breast Cancer
Read More
Page 160 of 196
Results 1591 - 1600 of 1955